一年一度的全球肿瘤学术界饕餮盛宴——美国临床肿瘤学会（ASCO）年会将于美国当地时间2022年6月3~7日召开。本刊特梳理了本届年会上结直肠癌领域的重磅临床研究进展作为端午佳节的大礼，让我们先睹为快！

 

口头报告

<Oral Abstract Session>

地点：Arie Crown Theater

时间：2022年6月6日周一 | 22:45 – GMT+8 01:45

一项对比mFOLFOX6或CAPOX用于局部晚期结肠癌患者围手术期化疗的多中心、随机3期试验

标题：Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial

摘要号：3500

报告人: Huabin Hu 

TAUTEM——对比新辅助治疗后局部切除（TEM）与全直肠系膜切除术（TME）治疗（T2T3sN0M0）直肠癌的非劣势多中心前瞻性随机对照研究：术前、手术和病理学结局

 

标题：Noninferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 (T2T3sN0M0) undergoing neoadjuvant treatment and local excision (TEM) versus total mesorectal excision (TME): Preoperative, surgical, and pathological outcomes—The TAUTEM-study. 

 

摘要号：3501

 

报告人: Xavier Serra-Aracil 

 

II期研究STAR-TREC：对于早期直肠癌，我们可以通过观察等待或放化疗后的经肛门手术来挽救直肠癌吗？

 

标题：STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?

 

摘要号：3502

 

报告人: Simon Parkinson Bach 

 

随机间歇性或连续性帕尼单抗联合FOLFIRI（FOLFIRI/PANI）用于RAS/BRAF野生型转移性结直肠癌患者的一线治疗 ：IMPROVE研究。 

 

标题：Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wildtype (wt) metastatic colorectal cancer (mCRC): The IMPROVE study. 

 

摘要号：3503

 

报告人: Antonio Avallone

 

STRATEGIC-1：不可切除野生型KRAS/NRAS/BRAF转移性结直肠癌的多线治疗试验——一项GERCOR-PRODIGE随机开放标签III期研究

 

标题：STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/ NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study. 

 

摘要号：3504

 

报告人: Benoist Chibaudel 

 

改良FOLFOXIRI联合帕尼单抗（mFOLFOXIRI/PAN）对比mFOLFOX6/PAN作为不可切除 RAS 和 BRAF野生型转移性结直肠癌患者的初始治疗：GONO的 III 期随机TRIPLETE 研究结果 

 

标题：Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO. 

 

摘要号：LBA3505

 

报告人: Chiara Cremolini 

 

FOLFOXIRI +贝伐珠单抗vs FOLFOX/FOLFIRI +贝伐珠单抗在最初不可切除右侧结直肠肝转移（CRLM）和/或RAS / BRAFV600E突变原发肿瘤患者中的比较：荷兰结直肠癌组的III期CAIRO5研究。

 

标题：FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group. 

 

摘要号：LBA3506

 

报告人: Cornelis J. A

 

对比伴不可切除转移结肠癌患者全身治疗前切除与不切除原发肿瘤的随机临床试验

 

标题：Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. 

 

摘要号：LBA3507

 

报告人: Nuh N. Rahbari

 

阿替珠单抗联合改良DCF（多西紫杉醇、顺铂和 5-氟尿嘧啶）作为转移性或局部晚期鳞状细胞肛门癌的一线治疗：一项SCARCE-PRODIGE 60随机 II 期研究 

 

标题：Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study. 

 

摘要号：3508

 

报告人: Stefano Kim 

 

壁报讨论会

 

< Poster Discussion Session >

 

地点：In-Person & Live Stream

 

时间：2022年6月4日周六 | 21:00 – GMT+8 00:00

 

纳武单抗联合FOLFOXIRI/贝伐珠单抗作为晚期RAS / BRAF突变结直肠癌患者一线治疗的II期研究：NIVACOR试验（GOIRC-03-2018）

 

标题：Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018). 

 

摘要号：3509

 

报告人: Angela Damato 

 

CheckMate 142——Nivolumab（NIVO） ± ipilimumab （IPI）在微卫星不稳定性高/错配修复缺陷转移性结直肠癌患者的五年随访结果

 

标题：Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. 

 

摘要号：3510 

 

报告人: Michael J. Overman

 

对比新辅助nivolumab、ipilimumab和celecoxib用于MMR显著和MMR缺陷结肠癌的NICHE研究的最终临床分析

 

标题：Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. 

 

摘要号：3511

 

报告人:Yara L. Verschoor 

除放化疗外，接触式 X 线近距离放射治疗可改善早期 cT2 - T3直肠腺癌的器官保存率：OPERA 随机试验（ NCT02505750 ）的 3 年结果

 

标题：Contact x-ray brachytherapy (Papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2-T3 rectal adenocarcinoma: The 3- year results of OPERA randomized trial (NCT02505750).

 

摘要号：3512

 

报告人:Jean-Pierre Gerard  

 

卡培他滨联合伴随放疗后使用durvalumab（MEDI4736）作为直肠癌术前治疗的II期PANDORA研究最终结果

 

标题：A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results. 

 

摘要号：LBA3513

 

报告人:Stefano Tamberi  

 

低直肠癌的治愈性放化疗：多中心II期试验的主要临床结局

 

标题：Curative chemoradiation for low rectal cancer: Primary clinical outcomes from a multicenter phase II trial. 

 

摘要号：LBA3514

 

报告人:Lars Henrik Jensen 

 

初次手术后进行选择性放化疗对比常规术前放化疗用于MRI 阴性周缘的局部晚期直肠癌患者：一项多中心、随机、开放、非劣效3 期研究

 

标题：Primary surgery followed by selective radiochemotherapy versus conventional preoperative radiochemotherapy for patients with locally advanced rectal cancer with MRI-negative circumferential margin (PSSR): A multicenter, randomized, open-label, noninferiority, phase 3 trial. 

 

摘要号：3515

 

报告人:丁克峰

 

腹腔镜辅助与开放手术治疗低直肠癌（LASRE）的短期结局：一项多中心、随机对照试验摘要号：3516

 

标题：Short-term outcomes of laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): A multicenter, randomized, controlled trial. 

 

报告人:池畔

 

免疫活检评分（ISB）的国际验证以指导直肠癌患者观察等待策略的选择和监测

 

标题：International validation of the Immunoscore-biopsy (ISB) to guide selection and monitoring of patients treated with watch-and-wait (WW) strategy for rectal cancer. 

 

摘要号：3517

 

报告人:Franck Page  

 

RAS /BRAF野生型转移性结直肠癌患者的血浆RAS动力学和抗EGFR再激活效应：REMARRY和 PURSUIT研究

 

标题：Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials. 

 

摘要号：3518

 

报告人:Yoshinori Kagawa 

 

在FOLFIRI联合西妥昔单抗诱导治疗后，对比5-FU联合贝伐珠单抗与继续FOLFIRI联合西妥昔单抗治疗的随机III期FIRE-4研究（AIO KRK-0114）次要终点的报告

 

标题：Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114). 

 

摘要号：3519

 

报告人:Sebastian Stintzing, Charite 

 

帕尼单抗联合或不联合曲美替尼治疗晚期结直肠癌的抗EGFR再激发治疗的2期研究

 

标题：Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. 

 

摘要号：3520

 

报告人:Christine Megerdichian Parseghian